Journal of Blood Disorders & Transfusion

Ferroptosis and Its Emerging Significance in Hematologic Disorders and Blood Cell Biology

Seungho Yeom^* Department of Laboratory Medicine and Transfusion Medicine, Korea University College of Medicine, Se, South Korea
^*Correspondence: Seungho Yeom, Department of Laboratory Medicine and Transfusion Medicine, Korea University College of Medicine, Se, South Korea, Email:

Received: 31-Mar-2026, Manuscript No. JBDT-26-31757; Editor assigned: 02-Apr-2026, Pre QC No. JBDT-26-31757 (PQ); Reviewed: 16-Apr-2026, QC No. JBDT-26-31757; Revised: 23-Apr-2026, Manuscript No. JBDT-26-31757 (R); Published: 30-Apr-2026, DOI: 10.4172/2155-9864.26.17.648

Description

Ferroptosis is a regulated form of cell death characterized by iron-dependent lipid damage within cellular membranes. Unlike apoptosis, necrosis, and autophagy, this process is driven primarily by oxidative injury that accumulates in phospholipids rich in polyunsaturated fatty acids. During the last decade, ferroptosis has attracted considerable attention in biomedical research because of its connection with iron metabolism, redox balance, and cellular survival. These biological activities are particularly relevant to Hematology, where iron serves an essential role in erythropoiesis, oxygen transport, and numerous enzymatic reactions.

Blood formation relies on a carefully balanced environment in which hematopoietic stem cells produce mature blood elements while maintaining their own population through self-renewal. Iron availability directly influences many of these activities. Excess iron, however, can generate reactive oxygen species through chemical reactions that damage lipids, proteins, and nucleic acids. Ferroptosis emerges when antioxidant defences are unable to prevent extensive lipid peroxidation. This event results in structural disruption of cellular membranes and ultimately cell death.

One of the most important protective systems against ferroptosis involves glutathione and glutathione peroxidase 4. Glutathione functions as an intracellular antioxidant, while glutathione peroxidase 4 removes harmful lipid peroxides. When glutathione levels decline or enzyme activity becomes insufficient, lipid oxidation progresses rapidly. Cells with elevated iron content may become especially susceptible because iron accelerates oxidative reactions. These observations have created significant interest in understanding how ferroptosis contributes to bloodrelated diseases.

The relationship between ferroptosis and Leukemia has become an active area of investigation. Leukemic cells often display altered metabolic pathways that support uncontrolled proliferation. Many studies have reported changes in iron uptake, storage, and utilization within malignant hematopoietic cells. Elevated iron concentrations may increase vulnerability to ferroptosis death under specific conditions. Researchers have therefore examined whether therapeutic induction of ferroptosis could reduce leukemic cell survival. Experimental findings suggest that certain compounds can trigger lipid peroxidation and suppress growth of Leukemia cells. Such observations indicate that ferroptosis-based strategies may complement existing treatment approaches in the future.

Acute myeloid Leukemia provides a notable example of the potential relevance of ferroptosis. This malignancy is characterized by the accumulation of immature myeloid cells in bone marrow and peripheral blood. Conventional treatments often include chemotherapy and, in selected cases, stem cell transplantation. Resistance to treatment remains a significant concern. Some investigations have demonstrated that leukemic cells resistant to conventional agents may retain sensitivity to ferroptosis-inducing compounds. This has encouraged additional research aimed at identifying molecular targets associated with iron metabolism and oxidative stress pathways.

Lymphoid malignancies have also been examined in relation to ferroptosis. Abnormalities in antioxidant systems, iron handling proteins, and lipid metabolism have been detected in several lymphoma and Leukemia subtypes. These findings suggest that ferroptosis mechanisms may influence disease progression and response to therapy. Further studies are needed to clarify how these pathways interact with genetic and environmental factors that contribute to hematologic cancers.

Beyond malignant disorders, ferroptosis may influence noncancerous hematologic conditions. Iron overload syndromes represent one area of interest. Excessive iron accumulation can occur as a consequence of hereditary disorders, repeated transfusions, or ineffective erythropoiesis. Elevated iron levels increase oxidative stress and may damage tissues throughout the body. Ferroptosis has been proposed as one mechanism through which excess iron contributes to cellular injury. Understanding these processes may improve knowledge regarding organ dysfunction associated with chronic iron overload.

Pharmacologic modulation of ferroptosis represents a developing field. Some compounds are designed to promote ferroptosis in malignant cells, whereas others aim to suppress ferroptosis in conditions where excessive cell death contributes to pathology. The challenge lies in achieving selective effects that preserve healthy tissues while targeting disease-associated processes. Continued research is expected to improve understanding of dose requirements, safety considerations, and clinical applicability.

Conclusion

Ferroptosis has expanded the understanding of how iron metabolism, oxidative stress, and lipid biology influence hematologic health and disease. The process offers a distinctive perspective on mechanisms that affect blood cell survival, bone marrow function, and malignant transformation. Evidence accumulated from experimental and translational studies suggests that ferroptosis participates in a variety of hematologic conditions, ranging from Leukemia and lymphoma to iron overload disorders and abnormalities of erythrocyte physiology.